-
Calnexin Shapes CFTR Variant Rescue and Drug Response
2026-09-20
Tedman et al. systematically examined how the ER chaperone calnexin influences expression and pharmacological rescue across 232 clinical CFTR variants. Their deep mutational scanning study shows that calnexin dependence is strongly variant- and domain-specific, providing a mechanistic framework for interpreting heterogeneous responses to CFTR modulators and designing more individualized cystic fibrosis research strategies.
-
Meropenem for Carbapenem Resistance Research
2026-09-19
Meropenem is a β-lactam antibiotic carbapenem for linking antibacterial phenotypes with carbapenemase, plasmid-transfer, and infection-model data. This workflow-focused guide shows how to control compound handling, design comparative assays, and interpret resistance results without confusing research observations with clinical treatment decisions.
-
Dual-Recombinase Tracing Tests Mouse Neo-Oogenesis
2026-09-18
Xie, Zhou, and Zheng use complementary Cre-loxP and Dre-rox lineage-tracing systems to test whether postnatal ovarian cells generate new oocytes in mice. Across physiological aging and busulfan-induced ovarian injury, the study detected no labeled growing oocytes or metaphase II eggs from non-pre-existing ovarian cells, strengthening the evidence against in vivo postnatal neo-oogenesis.
-
Ivermectin Workflows for Parasitology Research
2026-09-18
Build reproducible parasite assays with Ivermectin by controlling solvent, concentration, exposure time, and storage. This workflow also shows how a recent Gasdermin C study can improve assay interpretation without overstating evidence for oncology applications.
-
Nirmatrelvir: From 3CLpro Mechanism to Translation
2026-09-17
Nirmatrelvir (PF-07321332) offers translational researchers a well-defined way to connect SARS-CoV-2 polyprotein processing with measurable replication inhibition. This thought-leadership guide interprets the 3CLpro mechanism, evaluates docking evidence, outlines assay strategy, and positions a quality-controlled research reagent within antiviral therapeutics research.
-
Dual HER2–VEGFR-2 Targeting in Breast Cancer
2026-09-17
A 2026 study examined Lapatinib and Telatinib as a dual tyrosine kinase strategy in HER2-negative MDA-MB-231 triple-negative breast cancer cells. Combined treatment reduced proliferation, invadopodia formation, and two-dimensional tube formation, supporting further phenotype-first investigation while leaving direct target engagement and combination synergy unresolved.
-
MOG (35-55) Peptide: EAE Workflow Guide
2026-09-16
Build reproducible experimental autoimmune encephalomyelitis studies with a defined myelin oligodendrocyte glycoprotein peptide, from dissolution and dosing to pathway-aware readouts. This guide connects practical MOG (35-55) workflows with emerging PARP7–STAT1/STAT2 biology for more informative multiple sclerosis research.
-
Belinostat (PXD101): An Assay Design Framework
2026-09-16
Belinostat (PXD101) is a hydroxamate-type pan-HDAC inhibitor that connects chromatin acetylation with cell-cycle and cancer phenotypes. This article develops an assay-centered framework for interpreting its bladder, prostate, and spliceosome-related research applications without overstating cross-model evidence.
-
Triiodothyronine (T3) in Adipocyte Thermogenesis
2026-09-15
Use Triiodothyronine (T3) as a controlled endocrine perturbation to dissect thermogenic gene regulation, thyroid hormone receptor activation, and cellular metabolism in adipocyte models. This workflow pairs T3 dose–response testing with the SETD7–Adcy7–Sirt1–Creb1 axis highlighted in a recent obesity study, creating a practical bridge between molecular signaling and metabolic phenotyping.
-
EdU Imaging Kits (Cy3) for S-Phase Assays
2026-09-15
EdU Imaging Kits (Cy3) provide a denaturation-free way to measure DNA synthesis in microscopy and flow cytometry workflows. The approach is especially useful for connecting proliferation phenotypes with senescence-related cancer biology, drug response, and genotoxicity testing.
-
Resazurin Sodium Salt for Wnt Bone Assays
2026-09-14
Resazurin sodium salt can add a sensitive metabolic checkpoint to Wnt and bone-remodeling studies. This article explains how to use its redox signal alongside osteogenic, molecular, and imaging endpoints without mistaking metabolic activity for direct pathway engagement.
-
Telomere-Targeting Drugs in Latent HIV-1 Reservoirs
2026-09-14
The reference study shows that HIV-1 infection and latency are associated with telomere elongation in primary memory CD4+ T cells and Jurkat-derived models. It further demonstrates that the telomere-targeting agent BRACO19 preferentially induces apoptosis in infected cultures through a γ-H2AX-associated damage or telomere-uncapping response, highlighting a potential vulnerability of the HIV reservoir.
-
Naloxone Hydrochloride: Mechanism and Research Use
2026-09-13
Naloxone hydrochloride is a competitive opioid receptor antagonist used to interrogate μ-, δ-, and κ-opioid receptor signaling. This article connects its chemical specifications and receptor pharmacology with opioid addiction and withdrawal studies, while separating established evidence from product-reported neural stem cell proliferation modulation.
-
ICAA, RIP3, and Cardiac Hypertrophy
2026-09-12
A 2026 Cellular Signalling study identifies isochlorogenic acid A as a direct regulator of RIP3 in angiotensin II- and pressure overload-induced cardiac hypertrophy. Its central advance is the separation of RIP3-driven hypertrophic remodeling from canonical MLKL-dependent necroptosis, with the RIP3/CaMKII axis emerging as a mechanistically distinct target.
-
CA-074: Precision Cathepsin B Inhibition Workflows
2026-09-12
CA-074 enables selective interrogation of cathepsin B in biochemical assays, cell-death models, cancer metastasis, neurotoxicity, immune response modulation, and plant senescence research. This workflow-focused guide shows how to separate cathepsin B effects from broader cysteine-protease activity while improving dosing, controls, and troubleshooting.